NDA 208419: Complete Response Letter
A complete response letter is FDA's decision not to approve an application as submitted. See NDA 208419's history or Actavis's company page.
On Sep 26, 2017, FDA declined to approve NDA 208419 (NDA 208419) from Actavis, L.L.C. in its present form, citing facility inspections, microbiology. The application was later approved.
- Letter date: Sep 26, 2017
- Application: NDA 208419
- Since then: Approved
During recent inspection of Sindan-Pharma S.R.L (FEI: 3005566806) manufacturing facility for this application, our field investigators conveyed deficiencies to the representative of the facility. Satisfactory resolution of these deficiencies is required before...โฆ openFDA did not return the full text just now. Open it in the letter search.
- PemetrexedJun 26, 2018 ยท NDA 208419 ยท later approved
- Company
- Actavis, L.L.C.
- Application
- NDA 208419
- Status in openFDA
- Approved
- Review division
- Office of Hematology and Oncology Products
FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters